Your browser doesn't support javascript.
Impact of COVID19 pandemic on the incidence of health-care associated Clostridioides difficile infection.
Merchante, Nicolás; Chico, Pablo; Márquez-Saavedra, Esther; Riera, Gerónima; Herrero, Rocío; González-de-la-Aleja, Pilar; Aller, Ana I; Rodríguez, Juan Carlos; Rodríguez-Fernández, Miguel; Ramos, José Manuel; Trigo-Rodríguez, Marta; Merino, Esperanza.
  • Merchante N; Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla, Sevilla, Spain. Electronic address: nicolasmerchante@gmail.com.
  • Chico P; Servicio de Medicina Preventiva, Hospital General Universitario de Alicante, Instituto de Investigación Biomédica de Alicante (ISABIAL), Alicante, Spain. Electronic address: chico_pab@gva.es.
  • Márquez-Saavedra E; Servicio de Farmacia, Hospital Universitario de Valme, Sevilla, Spain. Electronic address: esther.marquez.sspa@juntadeandalucia.es.
  • Riera G; Servicio de Farmacia, Hospital General Universitario de Alicante, Instituto de Investigación Biomédica de Alicante (ISABIAL), Alicante, Spain. Electronic address: riera_ger@gva.es.
  • Herrero R; Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla, Sevilla, Spain. Electronic address: rocio.herrero.delrio@gmail.com.
  • González-de-la-Aleja P; Unidad de Enfermedades Infecciosas, Hospital General Universitario de Alicante, Instituto de Investigación Biomédica de Alicante (ISABIAL), Alicante, Spain. Electronic address: pilar.gonzalez01@goumh.umh.es.
  • Aller AI; Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla, Sevilla, Spain. Electronic address: anai.aller.sspa@juntadeandalucia.es.
  • Rodríguez JC; Servicio Microbiología, Hospital General Universitario de Alicante, Instituto de Investigación Biomédica de Alicante (ISABIAL), Alicante, Spain. Electronic address: rodriguez_juadia@gva.es.
  • Rodríguez-Fernández M; Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla, Sevilla, Spain. Electronic address: migrodfer92@gmail.com.
  • Ramos JM; Servicio de Medicina Interna, Hospital General Universitario de Alicante, Instituto de Investigación Biomédica de Alicante (ISABIAL), Alicante, Spain. Electronic address: jose.ramosr@umh.es.
  • Trigo-Rodríguez M; Unidad de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla (IBiS), Universidad de Sevilla, Sevilla, Spain. Electronic address: marta.trigo88@gmail.com.
  • Merino E; Unidad de Enfermedades Infecciosas, Hospital General Universitario de Alicante, Instituto de Investigación Biomédica de Alicante (ISABIAL), Alicante, Spain. Electronic address: merinoluc@gmail.com.
Anaerobe ; 75: 102579, 2022 Jun.
Article in English | MEDLINE | ID: covidwho-1814098
ABSTRACT

OBJECTIVE:

To investigate the impact of COVID19 pandemic on the incidence of health-care associated Clostridioides difficile infection (HA-CDI).

METHODS:

Retrospective study conducted in the Hospital Universitario de Valme (HUV) and the Hospital General Universitario de Alicante (HGUA) in Spain between January 2019 and February 2021. The study period was divided into non-COVID19 period (2019 and months from 2020 to 2021 with ≤30 hospitalized COVID19 patients) and COVID19 period (months from 2020 to 2021 with >30 COVID19 patients). HA-CDI incidence rates (IR) were calculated as the number of new CDI cases per 10.000 occupied bed-days (OBD) and antimicrobial consumption by means of the defined daily dose (DDD) per 1000 OBD.

RESULTS:

During the COVID19 period, HA-CDI IR in the HUV was 2.6 per 10.000 OBD, which was lower than what was observed during the non-COVID19 period (4.1 per 10.000 OBD; p = 0.1). In the HGUA, HA-CDI IR during COVID19 period was 3.9 per 10.000 OBD, which was not significantly different to the IR observed during the non-COVID19 period (3.7 per 10.000 OBD; p = 0.8). There was a slight increase in the total antibiotic consumption during COVID19 period in both hospitals, with significant increases of certain high-risk antibiotics as cephalosporins. CONCLSUSIONS HA-CDI incidence has not increased during the COVID19 pandemic in two tertiary centers in Spain, in spite of a slightly higher antibiotic consumption during the COVID19 period in both hospitals. These findings suggest that, in the presence of strict infection control measures, hospital antibiotic consumption might have a lower impact than expected on HA-CDI.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cross Infection / Clostridioides difficile / Clostridium Infections / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Anaerobe Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cross Infection / Clostridioides difficile / Clostridium Infections / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Anaerobe Year: 2022 Document Type: Article